Table 2.
Comparison of major baseline, disease and treatment characteristics between responders and non-responders SAARD patients.
| FEATURES | RESPONDERS N = 535 (%) |
NON-RESPONDERS N = 70 (%) | P-value |
|---|---|---|---|
| Demographics | |||
| Female gender | 384 (71.77) | 48 (68.57) | 0.6764 |
| Age median, min-max, years | 57, 16–91 (530*) | 63.5, 24-86 | 0.045 |
| Presence of any comorbidity | 130/528* (24.62) | 32 (45.71) | 0.0003 |
| Treatment status | |||
| No treatment | 40 (7.47) | 1 (1.42) | 0.0727 |
| Extended treatment modifications | 115 (21.49) | 3 (4.28) | 0.0001 |
| Partial treatment modifications | 91 (17.00) | 13 (18.57) | 0.8750 |
| No treatment modifications | 289 (54.01) | 53 (75.71) | 0.0009 |
| Diagnoses | |||
| Systemic vasculitis | 50 (9.34) | 17 (24.28) | 0.0004 |
| Rheumatoid arthritis | 152 (28.41) | 16 (22.85) | 0.4044 |
| Systemic lupus erythematosus | 101 (18.87) | 17 (24.28) | 0.3611 |
| Sjögren's syndrome | 51 (9.53) | 7 (10) | 0.9275 |
| Systemic sclerosis | 11 (2.05) | 3 (4.28) | 0.2135 |
| Idiopathic inflammatory myositis | 23 (4.29) | 5 (7.14) | 0.4457 |
| Seronegative arthritis | 121 (22.62) | 5 (7.14) | 0.0045 |
| Familial Mediterranean fever | 4 (0.74) | 0 (0) | 0.3799 |
| IgG4-related disease | 1 (0.18) | 1 (1.42) | 1.0000 |
| Antiphospholipid syndrome | 14 (2.61) | 2 (2.85) | 0.2182 |
| Polymyalgia rheumatica | 18 (3.36) | 0 (0) | 0.7067 |
| Behcet's disease | 4 (0.74) | 0 (0) | 0.2496 |
| Still's disease | 7 (1.30) | 0 (0) | 1.0000 |
| Mixed connective tissue diseases | 3 (0.56) | 1 (1.42) | 1.0000 |
| Disease Duration, median, min-max, years | 10, 0.2–47 (512*) | 12, 1–40 (65*) | 0.4254 |
| Treatment regimens | |||
| Glucocorticoids | 202 (37.75) | 40 (57.14) | 0.0028 |
| Mycophenolate mofetil | 43 (8.03) | 33 (47.14) | <0.0001 |
| Azathioprine | 36 (6.72) | 3 (4.28) | 0.6062 |
| Methotrexate | 169 (31.58) | 14 (20) | 0.0648 |
| Leflunomide | 31 (5.79) | 3 (4.28) | 0.7860 |
| Hydroxychloroquine | 92 (17.19) | 8 (11.42) | 0.2934 |
| TNF inhibitors | 130 (24.29) | 5 (7.14) | 0.0020 |
| Ustekinumab | 6 (1.12) | 0 (0) | 1,0000 |
| IL-1 inhibitors | 18 (3.36) | 0 (0) | 0.6147 |
| IL-6 inhibitors | 42 (7.85) | 2 (2.85) | 0.2158 |
| IL-17 inhibitors | 17 (3.17) | 1 (1.42) | 0.7094 |
| Rituximab | 22 (4.11) | 21 (30) | <0.0001 |
| JAK inhibitors | 4 (0.74) | 1 (1.42) | 0.4604 |
| Apremilast | 4 (0.74) | 0 (0) | 1.0000 |
| Abatacept | 4 (0.74) | 1 (1.42) | 0.4604 |
| Belimumab | 7 (1.30) | 3 (4.28) | 0.0981 |
| Colchicine | 5 (0.93) | 1 (1.42) | 0.5234 |
| Cyclosporine | 26 (4.85) | 3 (4,28) | 1.0000 |
| Cyclophosphamide | 2 (0.37) | 3 (4.28) | 0.0125 |
| Intravenous immunoglobulin G | 2 (0.37) | 1 (1.42) | 0.3089 |
| Disease activity | |||
| Remission | 404/530* (76.22) | 56 (80) | 0.5815 |
| Low | 93/530* (17.54) | 10 (14.28) | 0.6090 |
| Moderate | 29/530* (5.47) | 3 (4.28) | 1.0000 |
| High | 4/530* (0.75) | 1 (1.42) | 0.4634 |
Abbreviations: *: Available data; IgG4: Immunoglobulin G number 4; IL: Interleukin; JAK: Janus kinase.